drugset / Trial / NCT00835549
Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study is to compare the relative bioavailability of cefdinir for oral suspension 250 mg/5mL (manufactured and distributed by TEVA Pharmaceuticals USA) with that of OMNICEF® for oral suspension, 250 mg/5mL (Abbott) in healthy, adult, non-smoking subjects under non-fasting conditions.
Timeline
- Start
- 2005-03
- Primary completion
- 2005-03
- Completion
- 2005-03
Outcome
Met primary endpoint
registry Ratio of the T/R geometric mean x 100 98.6 (90% CI 94.8 to 102) NCT00835549 ↗
registry Ratio of the T/R geometric mean x 100 102 (90% CI 98.5 to 105) NCT00835549 ↗
registry Ratio of the T/R geometric mean x 100 102 (90% CI 98.7 to 105) NCT00835549 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | cefdinir | Other / unclassified | 250 mg | Oral |
Indications
No indication recorded.